XPHvsIBRNETF Comparison
VS
State Street SPDR S&P Pharmaceuticals ETF (XPH) belongs to the US Health Care segment. iShares Neuroscience and Healthcare ETF (IBRN) is part of the Healthcare Technology segment. XPH's top 1 sector exposures are Healthcare. In contrast, IBRN's top sector exposures are Healthcare and Non-Corporate. XPH is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.47% for IBRN. XPH is up 15.31% year-to-date (YTD) with +$189M in YTD flows. IBRN performs worse with 2.14% YTD performance, and +$2M in YTD flows. Run a side-by-side ETF comparison of XPH and IBRN below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XPH vs IBRN performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/28/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XPH IBRN | -3.46%-1.26% | -6.38%-11.74% | +15.31%+2.14% | +32.72%+9.73% | +87.71%+72.73% | +43.55%n/a |
| Flows | XPH IBRN | -$76M- | +$14M+$2M | +$189M+$2M | +$209M+$2M | +$163M+$759K | +$162M- |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XPH IBRN | +22.86%+26.89% | +23.37%+26.73% | +20.82%+25.48% | +21.09%n/a |
| Max drawdown | XPH IBRN | -16.58%-26.38% | -16.58%-26.38% | -23.45%-34.98% | -30.87%n/a |
| Max drawdown duration | XPH IBRN | 70d70d | 70d70d | 322d338d | 1452dn/a |
Trading data
XPH | IBRN | |
Last sale 10/29/2026 at 1:30 PM | $65.18 | $33.29 |
| Previous close 10/28/2026 | $64.55 | $32.92 |
| Consolidated volume 10/28/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XPH | IBRN | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/29/2026 at 1:30 PM
Live
Closed
XPH | IBRN | |
|---|---|---|
| Last price | $65.18 | $33.29 |
| 1D performance | +0.98% | +1.11% |
| AuM | $454.72 M | $6.60 M |
| E/R | 0.35% | 0.47% |
Characteristics
XPH | IBRN | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | State Street Investment Management | iShares |
| Benchmark | S&P Pharmaceuticals Select Industry Index | NYSE FactSet Global Neuro Biopharma and MedTech Index |
| N° of holdings | 62 | 69 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | June 19, 2006 | August 24, 2022 |
| ESG | No | No |
Advertisement
Exposure
Countries
XPH
USA
89.77%
Other
10.23%
IBRN
USA
73.41%
Other
26.59%
Sectors
XPH
Healthcare
93.27%
Other
6.73%
IBRN
Healthcare
99.86%
Other
0.14%
Advertisement
Diversification
XPH
Total weight of top 15 holdings out of 15
34.13%
IBRN
Total weight of top 15 holdings out of 15
62.03%
Top 15 holdings
Data as of August 31, 2026
XPH
Amylyx Pharmaceuticals, Inc.
3.65%
Crinetics Pharmaceuticals, Inc.
3.60%
MBX Biosciences, Inc.
2.89%
Omeros Corp.
2.68%
Enliven Therapeutics, Inc.
2.28%
Nuvation Bio, Inc.
2.12%
Corcept Therapeutics, Inc.
2.11%
Eton Pharmaceuticals, Inc.
2.08%
Perrigo Co. Plc
1.91%
Edgewise Therapeutics, Inc.
1.85%
Nektar Therapeutics
1.83%
Merck & Co., Inc.
1.81%
Trevi Therapeutics, Inc.
1.80%
Tarsus Pharmaceuticals, Inc.
1.76%
Bristol Myers Squibb Co.
1.75%
IBRN
Praxis Precision Medicines, Inc.
5.21%
Dianthus Therapeutics, Inc.
4.96%
ACADIA Pharmaceuticals, Inc.
4.93%
Scholar Rock Holding Corp.
4.85%
Xenon Pharmaceuticals, Inc.
4.40%
argenx SE
4.37%
Arrowhead Pharmaceuticals, Inc.
4.26%
Biogen, Inc.
4.19%
Alkermes Plc
4.15%
PTC Therapeutics, Inc.
3.70%
Denali Therapeutics, Inc.
3.56%
Neurocrine Biosciences, Inc.
3.55%
Dyne Therapeutics, Inc.
3.38%
Edgewise Therapeutics, Inc.
3.30%
Axsome Therapeutics, Inc.
3.23%
Frequently asked questions about XPH and IBRN
How have the XPH and IBRN ETFs performed in 2026?
As of October 28, 2026, XPH is up 15.31% year-to-date (YTD), while IBRN has returned 2.14%. That puts XPH better performer ahead so far this year.
Which ETF is attracting more investor money: XPH or IBRN?
Year-to-date, the XPH ETF saw +$189M in flows, compared to +$2M for IBRN.
Which ETF is more volatile: XPH or IBRN?
Over the past year, XPH had a volatility of 23.37%, while IBRN experienced 26.73%.
Which ETF is bigger: XPH or IBRN?
As of October 28, 2026, XPH holds $454.72 M in assets under management (AUM), while IBRN manages $6.60 M.
What sectors do the XPH and IBRN ETFs invest in?
XPH leans toward sectors like Healthcare. Meanwhile, IBRN focuses on Healthcare.
What are the top holdings of the XPH ETF and IBRN ETF?
XPH top holdings include Amylyx Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc. and MBX Biosciences, Inc.. IBRN holds in its top three: Praxis Precision Medicines, Inc., Dianthus Therapeutics, Inc. and ACADIA Pharmaceuticals, Inc..
Which ETF is more diversified: XPH or IBRN?
XPH holds 62 securities with 34.13% of its assets in the top 15. IBRN has 69 securities and a top 15 weight of 62.03%.
Advertisement
Latest news about XPH & IBRN
Donald Trump’s Executive Orders: ETF Bulls and Bears
January 24, 2025
XPH
Analyzing the Potential ETF Winners & Losers from The Weight-Loss Drug Craze
November 20, 2023
XPH
Advertisement
Advertisement
